Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations
Sickle cell disease (SCD) is a monogenic hemoglobinopathy with inequities in morbidity and care within and between countries. Prenatal somatic gene therapy is proposed but remains preclinical for SCD. This critical narrative review examines how such an intervention would interact with existing disparities and evaluates it in terms of autonomy, beneficence, non‐maleficence, and justice. SCD differs from conditions for which fetal intervention is established: fetal hemoglobin is protective, clinical manifestations generally arise after its postnatal decline, and newborn screening permits early preventive care. A prenatal intervention must therefore demonstrate a material advantage over timely postnatal management while exposing neither the pregnant person nor fetus to disproportionate procedural or product risk. Intended somatic treatment is not equivalent to heritable genome editing or embryo selection, although off‐target effects, mosaicism and unintended germline exposure require explicit investigation. There is currently no evidence that prenatal somatic gene therapy is cost‐effective or would overcome access barriers. Its reliance on fetal medicine, molecular, and manufacturing infrastructure could initially widen disparities. Clinical translation would be ethically defensible only after disease‐specific comparative evidence, independent oversight, non‐directive consent, lifelong follow‐up and a credible equitable‐access plan. Strengthening newborn screening and proven care remains the immediate justice priority.
Authors
- Annarita Miccio (ORCID: https://orcid.org/0000-0002-3409-9665)
- John Strouboulis (ORCID: https://orcid.org/0000-0002-6133-2872)
- Panicos Shangaris (ORCID: https://orcid.org/0000-0003-2750-8405)
- María Teresa Martín Monreal (ORCID: https://orcid.org/0009-0001-4959-0174)
- Evangelia Vlachodimitropoulou (ORCID: https://orcid.org/0000-0003-4330-6862)
- Sara El Hoss (ORCID: https://orcid.org/0000-0003-1711-2829)
- Eugene Oteng‐Ntim (ORCID: https://orcid.org/0000-0001-8867-2909)
- Kypros H. Nicolaides (ORCID: https://orcid.org/0000-0003-1266-0711)
- Ciro Chiappini (ORCID: https://orcid.org/0000-0002-9893-4359)
- Leila Sallie (ORCID: https://orcid.org/0009-0009-8644-0536)
- Morgan Bell-Ricketts Bell-Ricketts (ORCID: https://orcid.org/0009-0000-6299-044X)
- Lisa Joy Kaiser (ORCID: https://orcid.org/0009-0009-7672-0825)
- Alexandros Abdel Massih (ORCID: https://orcid.org/0009-0005-4348-1398)
- Aurora Riolini (ORCID: https://orcid.org/0009-0000-2219-4414)
- Saffron Rai (ORCID: https://orcid.org/0009-0007-0223-5590)
- Zuzanna Ammar
Institutions
- St Thomas' Hospital (GB)
- Inserm (FR)
- King's College London (GB)
- Université Paris Cité (FR)
- London Centre for Nanotechnology (GB)
- Harris Birthright Research Centre for Fetal Medicine (GB)
- Institut des Maladies Génétiques Imagine (FR)
Publication Details
- Journal
- Prenatal Diagnosis
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1002/pd.70314
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00